oxyacanthine profile

oxyacanthine: a putative calcium channel blocker; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxyacanthine : A macrocycle that is oxyacanthan that is substituted by methoxy groups at positions 6, 6', and 7, methyl groups at positions 2 and 2', and a hydroxy group at the 12' position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	442333
CHEMBL ID	509999
CHEBI ID	7853
SCHEMBL ID	459317
MeSH ID	M0244511

Synonym
CHEBI:7853 ,
C09598
548-40-3
oxyacanthine
CHEMBL509999
MLS002473156
smr001397248
HMS2194H09
SCHEMBL459317
AKOS030494633
oxyacanthine (vinetine)
DTXSID40893514
(1r,14s)-20,21,25-trimethoxy-15,30-dimethyl-8,23-dioxa-15,30-diazaheptacyclo[22.6.2.29,12.13,7.114,18.027,31.022,33]hexatriaconta-3(36),4,6,9(35),10,12(34),18,20,22(33),24,26,31-dodecaen-6-ol
Q27107597

Class	Description
macrocycle	A cyclic compound containing nine or more atoms as part of the cyclic system.
isoquinolines	A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
tertiary amino compound	A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
phenols	Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
bisbenzylisoquinoline alkaloid	A type of benzylisoquinoline alkaloid whose structures are built up of two benzylisoquinoline units linked by ether bridges. Various structural patterns resulting from additional bridging between the two units by direct carbon-carbon bridging or by methylenedioxy groups are common.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	31.6228	0.0447	17.8581	100.0000	AID485341
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	56.2341	0.6310	35.7641	100.0000	AID504339
USP1 protein, partial	Homo sapiens (human)	Potency	79.4328	0.0316	37.5844	354.8130	AID743255
TDP1 protein	Homo sapiens (human)	Potency	19.7347	0.0008	11.3822	44.6684	AID686978; AID686979
Smad3	Homo sapiens (human)	Potency	15.8489	0.0052	7.8098	29.0929	AID588855
67.9K protein	Vaccinia virus	Potency	14.2191	0.0001	8.4406	100.0000	AID720579; AID720580
IDH1	Homo sapiens (human)	Potency	29.0929	0.0052	10.8652	35.4813	AID686970
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
DNA repair protein RAD52 homolog isoform a	Homo sapiens (human)	AC50	9.2900	0.1500	12.0662	35.2100	AID652116
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (24)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID674580	Cytotoxicity against human U937 cells assessed as cell growth at 25 uM after 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID397125	Antimalarial activity against Plasmodium falciparum
AID397128	Inhibition of formyl-methionyl-leucyl-phenylalanine induced superoxide generation in PMNC
AID674573	Induction of rat C/EBPalpha expression transfected in human U937 cells at 25 uM after 24 hrs by luciferase reporter gene assay relative to ATRA	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID674572	Induction of rat C/EBPalpha expression transfected in human U937 cells after 24 hrs by luciferase reporter gene assay relative to ATRA	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID674575	Induction of rat C/EBPalpha expression transfected in human U937 cells at 3.1 uM after 24 hrs by luciferase reporter gene assay relative to ATRA	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID674579	Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID674582	Cytotoxicity against human U937 cells assessed as cell growth at 3.1 uM after 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (23.53)	18.7374
1990's	2 (11.76)	18.2507
2000's	2 (11.76)	29.6817
2010's	6 (35.29)	24.3611
2020's	3 (17.65)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.56%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (94.44%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
berberine [no description available]	2.41	2	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	1.98	1	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
berbamine [no description available]	7.44	2	phenylpropanoid
cepharanthine cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.	2.48	2	bisbenzylisoquinoline alkaloid; isoquinolines
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	2.17	1	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
laudanosine laudanosine: opium alkaloid	2.07	1	isoquinolines
tetrandrine tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity	2.07	1	bisbenzylisoquinoline alkaloid; isoquinolines
fangchinoline [no description available]	2.07	1	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite
trilobine trilobine: RN given refers to parent cpd	2.34	2	isoquinolines
berbamine [no description available]	2.07	1	bisbenzylisoquinoline alkaloid; isoquinolines
obamegine obamegine: RN given refers to cpd without isomeric designation	2.07	1	bisbenzylisoquinoline alkaloid; isoquinolines
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.07	1	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	7.31	1	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.42	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.42	2
2019 Novel Coronavirus Disease [description not available]	2.31	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.98	1
Adjuvant Arthritis [description not available]	1.99	1
Anasarca [description not available]	1.99	1
Delayed Hypersensitivity [description not available]	1.99	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	1.99	1

oxyacanthine

Description

Cross-References

Synonyms (14)

Drug Classes (5)

Protein Targets (8)

Potency Measurements

Other Measurements

Bioassays (24)

Research

Studies (17)

Study Types

oxyacanthine

Description

Cross-References

Synonyms (14)

Drug Classes (5)

Protein Targets (8)

Potency Measurements

Other Measurements

Bioassays (24)

Research

Studies (17)

Study Types

Related Drugs (13)

Related Conditions (8)